Leerink Partnrs Upgrades Inventiva (NASDAQ:IVA) to Strong-Buy

Inventiva (NASDAQ:IVA) was upgraded by Leerink Partnrs to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on the company. Guggenheim decreased their price target on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. HC Wainwright raised their price target on shares of Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Wolfe Research raised shares of Inventiva to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Leerink Partners assumed coverage on shares of Inventiva in a report on Monday. They issued an “outperform” rating and a $12.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Inventiva presently has an average rating of “Buy” and an average price target of $16.00.

Inventiva Stock Performance

IVA opened at $5.71 on Monday. Inventiva has a 12 month low of $2.11 and a 12 month high of $7.98. The business has a 50-day moving average of $4.38 and a two-hundred day moving average of $4.52.

Hedge Funds Weigh In On Inventiva

Hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new stake in Inventiva during the third quarter valued at about $116,000. Millennium Management LLC acquired a new stake in shares of Inventiva during the third quarter valued at approximately $649,000. Wealth Enhancement Advisory Services LLC lifted its position in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after acquiring an additional 9,212 shares in the last quarter. Finally, Creative Planning acquired a new position in Inventiva in the 2nd quarter worth approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.